To study the transcriptional regulation of the vasopressin gene in vitro, 3 kb of the 5Ј regulatory region of the rat vasopressin gene was isolated and subcloned, along with a series of various deletion mutants, into vectors containing the luciferase reporter gene. After transfecting these genes transiently into the human choriocarcinoma cell line JEG-3 along with a glucocorticoid receptor (GR) expression vector, transcriptional activity was quantitated using the luciferase assay. Forskolin, 8-bromo-cAMP, and protein kinase A catalytic subunit expression all markedly increased transcription from the 3-kb promoter. Analyses with deletion mutants of the promoter showed that two cAMP-responsive element (CRE)-like sequences (Ϫ227 to Ϫ220 bp and Ϫ123 to Ϫ116 bp) contribute to this positive regulation. Expression of KCREB, a dominant negative mutant of the cAMPresponsive element binding protein (CREB), suggested the involvement of CREB. Transfection of the activator protein 2 (AP2) DNA consensus sequence partially blocked transcription. Dexamethasone suppressed forskolin-stimulated expression. The negative effect of glucocorticoid was GR dependent and may be mediated by a mechanism not involving GR binding to DNA because it was independent of the putative glucocorticoid-responsive element previously reported in the vasopressin promoter (Ϫ622 to Ϫ608 bp) and was preserved in the shorter promoter constructs in which no glucocorticoid-responsive element-like sequence was found. Our data suggest that several trans-acting factors including CREB, AP2, and GR are likely to be involved in vasopressin gene transcription and that the positive and negative regulation of vasopressin gene transcription is complex. (Endocrinology 138: 5266 -5274, 1997) 
responsive element binding protein (CREB), suggested the involvement of CREB. Transfection of the activator protein 2 (AP2) DNA consensus sequence partially blocked transcription. Dexamethasone suppressed forskolin-stimulated expression. The negative effect of glucocorticoid was GR dependent and may be mediated by a mechanism not involving GR binding to DNA because it was independent of the putative glucocorticoid-responsive element previously reported in the vasopressin promoter (Ϫ622 to Ϫ608 bp) and was preserved in the shorter promoter constructs in which no glucocorticoid-responsive element-like sequence was found. Our data suggest that several trans-acting factors including CREB, AP2, and GR are likely to be involved in vasopressin gene transcription and that the positive and negative regulation of vasopressin gene transcription is complex. (Endocrinology 138: 5266 -5274, 1997) A RGININE vasopressin is a nonapeptide synthesized mainly in the hypothalamic nuclei of the brain (1) . Vasopressin synthesized in magnocellular neurons of the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus is transported through axons, stored in the neurohypophysis, and then released into the peripheral circulation to regulate body fluid tonicity, and possibly cardiovascular function (2, 3) . Vasopressin synthesized in parvocellular neurons of the PVN is released at the median eminence into the hypophyseal portal vein, where it regulates adrenocorticotropic hormone secretion from the anterior pituitary (4, 5) . Vasopressin is also synthesized in the suprachiasmatic nucleus of the hypothalamus and in some peripheral organs, although its functional role in these sites is not known (6) .
The vasopressin gene is approximately 2 kb in size and consists of 3 exons and 2 introns, encoding a signal peptide, vasopressin, neurophysin II, and a carboxy-terminal glycopeptide (7, 8) . After transcription, splicing and translation, the preprohormone, preprovasopressin, is cleaved by signal peptidase, making provasopressin, which contains the latter three peptides. The prohormone is sorted from the endoplasmic reticulum to secretory granules through the Golgi apparatus, during which it undergoes posttranslational modifications such as processing, amidation, and glycosylation, to yield the mature peptide secretory products (9) .
Regulation of vasopressin secretion is relatively well characterized (2) . Also, using immunohistochemical and molecular biologic techniques, the differential regulation of vasopressin expression in vivo has recently been clarified, with vasopressin expression in magnocellular neurons of the SON and PVN being stimulated by osmotic and hypovolemic stimuli, and that in parvocellular neurons being negatively regulated by glucocorticoid (10, 11) . However, the mechanisms of transcriptional regulation of the vasopressin gene within the cell are not well known. Hypothalamic vasopressin messenger RNA (mRNA) content is increased after water deprivation in hyperosmolar rats (12) (13) (14) (15) (16) (17) . Osmotic stimulation enhances cAMP production in the SON in the rat (18, 19) . cAMP is known to stimulate vasopressin gene expression (20, 21) , and putative cAMP-responsive elements (CREs) have been identified in the bovine vasopressin gene promoter (21) . Together, these data suggest a role for this pathway in the positive regulation of vasopressin gene transcription. In contrast, glucocorticoid has been shown to exert a negative effect on vasopressin gene expression (22) . The negative effect of glucocorticoid on vasopressin gene expression may have clinical significance. Vasopressin synthesized in hypothalamic parvocellular neurons, which is involved in stress-induced ACTH secretion, is negatively regulated by glucocorticoid (4, 10) . Also, glucocorticoid receptor (GR) are present in both parvocellular (23) as well as magnocellular vasopressinergic neurons, although in the latter only during hypoosmolality (24) ; this may explain the vasopressin hy-persecretion frequently observed in patients with chronic glucocorticoid insufficiency (25) .
To study the transcriptional regulation of the vasopressin gene in vitro, we isolated 3 kb of the 5Ј promoter region of the rat vasopressin gene, as well as a series of promoter deletion mutants, and fused these to a luciferase reporter gene. Because no homologous cell line derived from vasopressinergic neuron is available, these constructs were expressed in the human choriocarcinoma cell line JEG-3. Changes in promoter activity by various reagents were quantitated using the luciferase assay. We examined the roles of various intracellular signaling systems of potential physiological importance, including the protein kinase A (PKA) and GR pathways, in the regulation of vasopressin gene expression.
Materials and Methods

Cell culture
The human choriocarcinoma cell line JEG-3, obtained from D. Anderson (Harvard Medical School, Boston, MA), was cultured in RPMI1640 medium (Life Technologies, Gaithersburg, MD) or DMEM without phenol red supplemented with 10% FBS and antibiotics (50 U/ml penicillin and 50 g/ml streptomycin; Life Technologies) under a 5% CO 2 /95% atmosphere at 37 C. Culture media were changed twice a week, and the cells were subcultured once a week.
Plasmid constructions
An 8.2-kb EcoRI DNA fragment of the rat vasopressin gene, including 3-kb 5Ј flanking region, 2-kb structural gene containing three exons and two introns, and 3.2-kb 3Ј flanking region, was isolated from a rat genomic library in lambda phage as previously reported (26) . To isolate the 3-kb 5Ј flanking region of the gene, 292 bp of downstream region (positions Ϫ266 to ϩ26; transcription start site is designated as ϩ1) of the promoter sequence was first synthesized by the PCR with Taq DNA polymerase (Perkin-Elmer/Cetus Corp., Norwalk, CT) using sense and antisense oligonucleotide primers containing XhoI and KpnI restriction sites, respectively (shown by bold type) as described below:
Sense: 5Ј-TTTCTCGAGCCTCCCTGATTGCACAGCAC-3Ј Antisense: 5Ј-TTTGGTACCGGCACTGCGTGCAGCTCT-3Ј The PCR product was subcloned into the XhoI/KpnI sites of pBluescript IISK ϩ plasmid (Stratagene, La Jolla, CA), and the sequence was confirmed by dideoxy chain termination method. Then the remaining 2.7-kb length upstream region of the 5Ј flanking sequence was isolated from the original gene by endonuclease digestion, and ligated at the BalI site (Ϫ211) of the downstream region, thus completing the 3-kb fulllength 5Ј promoter (AVP3000; Ϫ3000 to ϩ26). Six serial shorter deletion mutants of the 5Ј promoter genes were also made by endonuclease digestions at unique restriction sites (AVP803, AVP441, AVP266, AVP211, AVP102, and AVP36; Ϫ803, Ϫ441, Ϫ266, Ϫ211, Ϫ102, and Ϫ36 to ϩ26, respectively). Also, various mutants, in which defined parts of the promoter sequences were deleted from AVP441, were made by site-directed mutagenesis (27) : [for AVP441D250Ϫ201, AVP441D150 -101, and AVP441D100 -71; Ϫ250 to Ϫ201, Ϫ150 to Ϫ101, and Ϫ100 to Ϫ71 bp of the promoter sequences were deleted, respectively; for AVP441DCRE1 and AVP441DCRE2, CRE1 (Ϫ227 to Ϫ220) and CRE2 (Ϫ123 to Ϫ116) were deleted, respectively; for AVP441DCAAT, the CCAAT box (Ϫ247 to Ϫ243) was replaced with GTCGA].
To make the vasopressin promoter/luciferase fusion genes, each promoter sequences was subcloned into BamHI/KpnI sites of a pXP1 plasmid containing the luciferase reporter gene (28) . Some of the vasopressin promoter constructs were also subcloned into a different luciferase vector pA3Luc (29) . As a positive control, the long terminal repeat of the rous sarcoma virus (RSV) promoter was subcloned into the pXP1 plasmid (pXP1/RSV).
To make a competitor plasmid to bind intracellular activator protein 2 (AP2) transcription factor, two oligonucleotides containing tandem AP2 consensus sequences found between Ϫ95 and Ϫ75 of the rat vasopressin promoter were synthesized as shown below (AP2 consensus sequences are shown by bold type):
Sense: 5Ј-GATCCTCCCCAGTGGCTCCCCAGGAGA-3Ј Antisense: 5Ј-AGCTTCTCCTGGGGAGCCACTGGGGAG-3Ј These two oligonucleotides were annealed, and cloned between HindIII/BamHI sites of the pBluescript IISK ϩ plasmid. pBluescript IISK ϩ was used as a control.
Transient plasmid transfections
JEG-3 cells were transfected transiently with each sequentially deleted or mutated vasopressin-luciferase fusion gene along with other expression vectors (as indicated) using the standard calcium phosphate precipitation method (30) . Cells of approximately 50% confluency in 60-mm diameter culture dishes were incubated for 3-4 h with CaPO 4 precipitates containing 3 g of DNA in total [0.6 g of each vasopressin plasmid, 0.3 g of GR expression vector (either wild-type or mutant), 0.3 g of a human GH (hGH) expression vector (pRSV-hGH) as an internal control (when indicated) (31), other plasmids for cotransfection experiments (as indicated), and pBS(ϩ) plasmid (Stratagene) as carrier plasmid to keep the total amount of transfected DNA constant], followed by 2 min of 15% glycerol shock. Cells were used for experiments 24 -48 h after the start of the transfection.
Evaluation of promoter activity
For the initial characterization, AVP3000 full-length promoter-luciferase fusion gene was used. In the subsequent experiments, AVP441, which contains all the putative CREs, was used to study the positive regulation by cAMP-PKA pathway, whereas AVP803, which includes putative glucocorticoid-responsive element (GRE) (Ϫ622 to Ϫ608), was used to study negative regulation by glucocorticoid.
Cells were treated with forskolin, an activator of adenylate cyclase, 8-bromo-cAMP (8Br-cAMP), a membrane permeable cAMP analog (Sigma Chemical Co., St. Louis, MO), the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA; Sigma), an activator of protein kinase C (PKC), or dexamethasone (Sigma), a potent synthetic glucocorticoid, with defined concentrations and time intervals. When the expression of different plasmid constructs was compared in the same experiment, pRSV-hGH (31) was cotransfected as an internal control, and hGH secreted into culture medium of each dish was measured by human GH RIA kit (Daiichi Isotope Co., Tokyo, Japan). Forskolin and dexamethasone were dissolved in ethanol, and TPA was dissolved in dimethyl sulfoxide, whereas 8Br-cAMP was dissolved in culture medium. Stock solutions for all reagents were made in 1000ϫ concentrations except 8Br-cAMP (100ϫ maximum), and 0.1% volume of the stock solution or solvent alone was added directly into the culture medium of each dish.
Luciferase assay
Luciferase assay was performed as previously described (32) with some modification. After the defined time of incubation with various reagents, cells were washed 2-3 times with phosphate buffer saline without Ca ϩϩ , Mg ϩϩ , harvested with lysis buffer containing 1% (vol/ vol) Triton X100, 25 mm glycylglycine, pH 7.8, 15 mm MgSO 4 , 4 mm EGTA, and 1 mm DTT, and the cell lysate was centrifuged. For the luciferase reporter assay, 100 l of each supernatant was added to 360 l of luciferase assay buffer containing 25 mm glycylglycine, pH 7.8, 15 mm MgSO 4 , 4 mm EGTA, 15 mm potassium phosphate, pH 7.8, 2 mm ATP, 1 mm DTT, and 0.5 mm coenzyme A (Sigma). Reactions were mixed in a luminometer (LKB Model 1251, Pharmacia, Stockholm, Sweden; or Berthold Lumat LB9501, Bundoora, Australia) by injection of 200 l of the luciferin solution containing 0.2 mm d-luciferin (Analytical Luminescence Laboratory, San Diego, CA, or Sigma), 25 mm glycylglycine, pH 7.8, 15 mm MgSO 4 , 4 mm EGTA and 2 mm DTT. Light output was measured for 20 sec at 25 C. The net light output was calculated by subtracting the background value from the value of each sample and displayed in arbitrary units. When hGH was used as internal control, each value of the net light output was divided by the hGH value of the corresponding dish, and displayed in arbitrary units.
Data analyses
Most of the experiments were carried out more than two times. Samples in each group of experiments were performed in triplicate or quadruplicate. All data were expressed as mean Ϯ se. When statistical analysis was performed, data were compared by one-way ANOVA with Duncan's multiple range test, and P values below 0.05 were considered significant.
Results
Regulation of vasopressin gene expression by the PKA and PKC pathways
We first studied the role of cAMP-mediated intracellular signaling system in the transcriptional regulation of the vasopressin gene. Forskolin (10 mm) had no effect on luciferase activity in cells transfected with RSV-luciferase (pXP1/RSV) constructs but significantly stimulated luciferase activity in cells transfected with the longest vasopressin-luciferase construct (AVP3000) in a time-dependent fashion, with the maximal stimulatory effect (5.5-fold) observed after a 5-h incubation (data not shown). We therefore used a 5-h incubation for forskolin in the subsequent experiments.
We then studied the dose-response effect of forskolin or other stimulation of the cAMP/PKA pathway in cells transfected with AVP441, which contains all of the putative cAMP-responsive elements (see below). Forskolin treatment for 5 h (0.1-100 mm) again stimulated vasopressin gene expression in a dose-dependent fashion, with the maximal effect at a concentration of 10 mm (Fig. 1A, left panel) . A similar effect was observed when cells were treated for 5 h with 8Br-cAMP (0.1-5 mm), a membrane permeable cAMP analog (Fig. 1A, right panel) . We also carried out cotransfection experiments using an expression vector of the PKA catalytic subunit a (PKAcat), kindly provided by Dr. Richard Maurer (33) . As expected, the expression of PKAcat markedly enhanced the vasopressin promoter transcription in a dose-dependent fashion (up to approximately 20-fold) (Fig.  1B) . Because PKA is known to be activated by cAMP, these results indicate that the cAMP/PKA pathway is a major positive regulator of vasopressin gene expression.
We also studied the effect of TPA, an activator of PKC, on vasopressin expression to determine the role of PKC-mediated intracellular signaling system in the transcriptional regulation of the vasopressin promoter. TPA (up to 1 mm) did not show any significant effects on vasopressin promoter activity (AVP3000) between 2 and 24 h following its addition (data not shown), indicating that at least under these experimental conditions, the PKC pathway is not a major regulator of vasopressin gene expression.
Regulation of vasopressin gene expression by glucocorticoid
To determine the role of glucocorticoid in the transcriptional regulation of the vasopressin gene, we first studied the effect of dexamethasone on vasopressin promoter transcription in JEG-3 cells expressing AVP803, which contains a putative GRE (Ϫ622 to Ϫ608 bp). Because JEG-3 cells express no intrinsic GR (34), the cells were cotransfected with a GR expression vector (35) , kindly provided by Dr. Ronald Evans, along with the vasopressin-luciferase construct. Dexamethasone by itself had no significant effect on luciferase activity in cells transfected with either vasopressin-luciferase or RSVluciferase (pXP1/RSV) constructs (data not shown). Dexamethasone (100 nm) coadministered with forskolin (10 mm) significantly suppressed forskolin-stimulated vasopressin promoter activity in a time-dependent fashion, with the maximal suppressive effects (31% of forskolin-stimulated activity) observed 5 h after the coaddition of forskolin and dexamethasone (data not shown). We therefore subsequently used 5 h of coincubation with dexamethasone and forskolin.
We examined the dose-dependent effect of dexamethasone on vasopressin expression using JEG-3 cells with the GR expression vector. Dexamethasone treatment for 5 h (1-1000 nm) at doses as low as 1 nm suppressed forskolin-stimulated vasopressin gene expression in a dose-dependent fashion, with maximal suppression seen at 10 nm ( Fig. 2A) . To confirm that the suppressive effect of dexamethasone is GRdependent, we carried out a titration experiment of GR expression vector cotransfection. No suppression by dexamethasone (100 nm) was observed without GR, whereas the suppressibility was enhanced as the amount of GR cotransfected increased (Fig. 2B) . These results together indicate that glucocorticoid exerts a negative effect on vasopressin gene expression, and the effect is GR dependent.
To determine the GR structural requirements for dexamethasone repression of vasopressin gene expression, JEG-3 cells were transfected with a vasopressin promoter-luciferase construct and various mutant GR expression vectors [also provided by Dr. Ronald Evans (35) ]. Dexamethasone treatment (100 nm) for 5 h again showed suppression of forskolinstimulated vasopressin promoter activity in cells cotransfected with wild-type GR expression vector (Fig. 3) . A similar negative effect was observed when the vasopressin promoter construct was cotransfected with a mutant GR in which the N-terminal transactivation domain was deleted (GRD77Ϫ262). In contrast, when the vasopressin promoter construct was cotransfected with another mutant GR in which the domain containing both zinc fingers was deleted (GRD428 -490), dexamethasone unexpectedly showed an enhancing rather than suppressive effect (Fig. 3) . 
Structural determinants of the vasopressin promoter required for regulation by the PKA and glucocorticoid pathways
When sequences of the vasopressin 5Ј promoter in rat, mouse, bovine, and human were compared (7, 8, 36 -38) , many areas were found to be well conserved, which encode potential cis-acting elements. A consensus nurr1/ nur77 DNA recognition sequence, G/A AAG C/G TC A/G (39) , is present at nucleotides Ϫ454 to Ϫ447 (AAAGCTCA). In addition, other potential cis-acting elements, such as the CAAT box, CRE, and AP2 sequences, were detected (Fig. 4) . To determine whether these putative cis-acting elements are responsible for the positive and negative regulation of rat vasopressin gene promoter transcription, we studied basal, forskolin (10 m)-, or forskolin (10 m) and dexamethasone (100 nm)-treated promoter activity in a series of the 5Ј deletion mutant constructs (AVP3000, 803, 441, 266, 211, 102, and 36) in JEG-3 cells (Fig. 5A) . Only a minimal increase (less than 3-fold) was observed in the promoterless plasmid (data not shown). Among the promoter constructs tested, the maximal activity was observed with the promoters AVP803 or AVP441, which were higher than that in full-length AVP3000, suggesting repressor activity in upstream element(s). Shorter constructs (AVP266 to AVP36) showed a clear decrease in absolute basal as well as forskolin-treated activity. However, the relative stimulation by forskolin was consistently more than 10-fold in all the deletion mutants including the shortest construct (AVP36), which lacks both putative CREs and the putative nurr1/nur77 binding site. Dexamethasone had a consistent suppressive effect of 30 -40% on forskolin-stimulated promoter activity, in constructs AVP3000 to AVP102, which included those lacking a putative GRE at nucleotides Ϫ622 to Ϫ608, and the potential nurr1/nur77 site noted above. Of interest, negative regulation by dexamethasone was not seen with AVP36, suggesting the possible presence of a negative GRE between Ϫ102 and Ϫ36 bp of the vasopressin promoter. Neither forskolin nor dexamethasone had a significant effect on RSV-luciferase (pXP1/RSV) expression (data not shown).
To better define the location of cis-acting element(s) of the rat vasopressin gene promoter involved in forskolin and glucocorticoid responsiveness, we studied basal, forskolin (10 m)-, or forskolin (10 m) and dexamethasone (100 nm)-treated promoter activity in a series of internal deletion mutants in which 30 -50 bp regions containing putative control elements were eliminated (Fig. 5B) . The two deletion mutants AVP441D250 -201 and AVP441D150 -101, each of which lacks a different one of the two putative CREs, when compared with the intact promoter, AVP441, showed a substantial decrease in the absolute level of basal and forskolin-stimulated transcriptional activity, whereas AVP441D100 -71, which lacks a tandem putative recognition site for AP2, had normal activity (Fig. 5B) . In all constructs, however, a similar relative degree of forskolin stimulation and dexamethasone suppression was observed.
To even more precisely identify the cis-acting element(s) required for positive and negative regulation, we studied basal, forskolin (10 m)-, or forskolin (10 m) and dexamethasone (100 nm)-treated promoter activity in another series of four mutant constructs; AVP441DCRE1, in which CRE1 (Ϫ228 to Ϫ221) was eliminated; AVP441DCRE2, in which CRE2 (Ϫ123 to Ϫ116) was eliminated; AVP441DCRE1/ DCRE2, in which both CREs were eliminated; and AVP441DCAAT, in which the putative cCAATc enhancer sequence (Ϫ246 to Ϫ243) was replaced with the sequence, gTCGAc (Fig. 5C) . Deletion of either CRE sequence alone had no effect, whereas deletion of both CREs resulted in a substantial (Ͼ50%) decrease in the absolute level of both basal and forskolin-stimulated transcriptional activity (Fig. 5C) . However, as in the constructs containing larger mutations (Fig. 5, A and B) , elimination of both CREs had no effect on the relative magnitude of forskolin stimulation (ϳ7-fold) and dexamethasone suppression (ϳ50%), both effects being similar to those seen in the wild-type construct, AVP441. Modification of the CAAT box had no effect on either the absolute or relative magnitude of vasopressin promoter response to forskolin or dexamethasone. Taken together, the results in Fig. 5 suggest that the two CRE-like sequences are important for both basal vasopressin gene transcription and the absolute level of response to forskolin, although the relative modulation of transcriptional activity by cAMP or glucocorticoid is not dependent on the presence of these DNA sequences.
Effects of cotransfection of KCREB, a dominant-negative inhibitor of CREB, or an AP2 competitor plasmid, on vasopressin promoter activity
To examine the role of cAMP-responsive element binding protein (CREB) in mediating forskolin-stimulated vasopressin gene expression, we cotransfected JEG-3 cells with AVP441-luciferase construct and with an expression vector encoding either CREB or KCREB (40) , the latter a dominantnegative form of CREB (Fig. 6A) . When KCREB was coexpressed with AVP441 (but not with AVP102, which lacks both putative CREs), both absolute basal and forskolinstimulated vasopressin promoter activities were significantly lower (less than 50%) than seen with CREB, although the relative level of forskolin stimulation (ϳ7-fold) was not affected by KCREB expression. That KCREB had no effect on basal or forskolin-stimulated transcription of construct AVP102 suggests that forskolin-mediated transcriptional activation of this construct may be mediated by a mechanism not involving CREB. We also cotransfected JEG-3 cells with AVP441-luciferase construct and with either AP2 competitor or control plasmids. Cotransfection of the competitor plas- mid significantly decreased the both basal and forskolinstimulated vasopressin expression (Fig. 6B ) compared with that of the control plasmid. The relative level of forskolin stimulation, however, was not affected.
Discussion
In this study, we characterized the transcriptional regulation of the rat vasopressin gene 5Ј promoter using a luciferase reporter system in the JEG-3 cell line. We confirmed that the rat vasopressin gene promoter is regulated positively by the cAMP/PKA pathway and additionally found it to be negatively regulated by glucocorticoid. Our data suggest that several cis-acting factors including CREB and AP2 are likely to be involved in both basal and stimulated transcriptional activities. However, all experimental interventions, including mutation of cis-acting elements, introduction of a dominant-negative trans-acting factor, and addition of competitor DNA, equally affected both basal and stimulated promoter activity (Fig. 5 ) and had no effect on the magnitude of PKA stimulation, which remained consistently approximately 7-fold above basal promoter activity. We also found that the negative effect of glucocorticoid is GR dependent and may be mediated by a mechanism not involving GR binding to DNA. Moreover, when the zinc finger domain was removed, GR activity remained ligand dependent but was switched from a repressor to an activator of vasopressin transcription. Finally, we found no evidence for PKC activation of vasopressin gene transcription.
Our results show that, as previously reported (20, 21, 41, 42) , forskolin, an activator of adenylate cyclase, or 8Br-cAMP, a membrane-permeable cAMP analog, potently stimulate vasopressin gene expression. A marked dose-dependent stimulatory effect was also observed with cotransfection of the catalytic subunit of a PKA expression vector (33) , further confirming the positive role of this pathway. In vivo studies in the rat have demonstrated accumulation of cAMP within the SON after hypertonic saline injection or salt loading (18, 19) , suggesting that this regulatory system may operate in intact organisms.
We further examined the cis-and trans-acting element(s) that may mediate the positive effect of the cAMP/PKA pathway. Because the rat 5Ј vasopressin promoter sequence has two putative CREs, a putative nurr1/nur77 element and four putative AP2 consensus sequences within 0.5 kb of the promoter (Fig. 4) , any of which might confer cAMP responsiveness (21, 36, 39) , we selectively mutated each of these DNA regions to ascertain their involvement in the positive regulation by forskolin. Elimination of DNA sequences between Ϫ3000 and Ϫ803 caused a consistent increase in basal and stimulated promoter activity, suggesting repressor properties in upstream element(s) in this region. Elimination of a consensus nurr1/nur77 site had no effect on positive or negative regulation of the vasopressin promoter. This element, present in two other neuroendocrine genes of the hypothalamic-pitutiary-adrenal axis that encode POMC and CRH, has been shown to bind the nurr1/nur77 subfamily of nuclear hormone receptors and mediate both positive and negative regulation by the PKA and GR pathways, respectively (39) . Deletion analysis showed that the elimination of either one of the two putative CREs within the vasopressin promoter had no effect, whereas removal of both CREs markedly diminished transcriptional activity, suggesting that both basal and forskolin-stimulated transcription is mediated by multiple CREs. This redundant mode of regulation has been described in the transcriptional control of promoters of various neuropeptide genes (43) . Pardy et al. (21) recently identified a CRE between Ϫ210 and Ϫ112 of the bovine vasopressin promoter [corresponding to CRE2 (Ϫ123 to Ϫ116) of the rat vasopressin promoter] using a relatively short construct that does not contain the CRE sequence corresponding to rat CRE1.
5Ј deletion constructs with less than 266 bp of promoter (AVP211, AVP102, and AVP36), internal deletion constructs lacking CRE1 (AVP441D250 -201), or CRE2 (AVP441D150 -101), as well as the double point deletion construct lacking both CRE1 and CRE2 (AVP441DCRE1/DCRE2) all share an intriguing characteristic: whereas the absolute level of basal and forskolin-stimulated transcriptional activity is regulated in all of these constructs, the relative increase in vasopressin promoter transcriptional activity following cAMP stimulation remains intact. The decrease in absolute basal activity may reflect a decreased ability of these mutated vasopressin promoter constructs to bind a cAMP-stimulated transcription factor such as CREB, which can support constitutive gene transcription in a phosphorylation-independent fashion via interaction of its Q2 domain with dTAF110, a component of the basal transcription factor TFIID (44) . The maintenance of the relative magnitude of transcriptional stimulation following PKA activation suggests that the degree of activation involves a process that is independent of the magnitude of promoter binding of the transcription factor, such as the phosphorylation of a transcription factor already bound to the promoter DNA sequence. Phosphorylation of CREB promotes the interaction of its KID domain with the KIX domain of CREB binding protein (CBP) to stimulate transcription (45) . Thus, a vasopressin promoter construct containing CRE mutations might bind CREB at a level 25% of that of an intact promoter and exhibit a basal transcription rate 25% that of the intact promoter. CREB phosphorylation following PKA stimulation might activate promoter-bound CREB to the same degree in both intact and mutated promoter constructs, resulting in the same fold stimulation, although to different absolute levels, of transcriptional activity. This is likely a general phenomonen that was not generally appreciated previously because of the relative insensitivity of past methods used to monitor transcriptional activity, in which mutations (e.g. within a CRE) affecting PKA-stimulated transcription were reported to alter the degree of transcriptional activation by PKA (46) .
To further define the nature of PKA-responsive factors involved in vasopressin promoter regulation, we examined the effect of KCREB, a dominant negative mutant of CREB (40) , upon vasopressin promoter transcription. Coexpression of KCREB clearly attenuated the basal and absolute level of forskolin-stimulated expression of AVP441, a vasopressin promoter containing two putative CREs, but again did not affect the relative increase in transcriptional activity following forskolin addition. One explanation for these results is that KCREB blocks binding of CREB to CREs at Ϫ220 and Ϫ120 bp in AVP441, resulting in reduced basal and stimulated transcriptional activity. That the residual forskolinstimulated activity following coexpression of AVP441 and KCREB may be due to binding of a PKA-stimulated factor (either CREB or another DNA binding protein such as AP2) to a non-CRE sequence is supported by the absence of effect of KCREB on PKA-stimulated transcriptional activation of AVP102, which lacks CRE motifs. The role of AP2 was tested as well, because this factor is also known to mediate cAMPstimulated transcriptional activation (47) . In an attempt to compete away any endogenous AP2-like binding factors, we cotransfected a plasmid harboring the same AP2-like sequences observed in Ϫ72 to Ϫ100 of the vasopressin promoter. This procedure also decreased vasopressin promoter activity, suggesting that AP2, or related factors that bind to these sequences, may play a positive role in vasopressin gene expression.
We found that glucocorticoid inhibited PKA-stimulated, but not basal transcription, that this effect was GR-dependent, and that the zinc finger domain, but not the N-terminal transactivation domain, was crucial for this suppressive effect. A similar effect was observed previously in the regulation of the human interleukin 6 promoter (48) . Although the zinc finger domain of GR is known to be necessary for DNA binding to GREs that stimulate gene transcription, the repressive effect of dexamethasone was observed in vasopressin promoter constructs which have no obvious GRE, suggesting that this effect may be caused not by DNA binding of GR, but perhaps by protein-protein sequestration (squelching) of a positive transcription factor by GR. Although such squelching could be an artifact caused by the transfection of excessive amounts of GR, this possibility was minimized by titration of the amount of GR transfected to the lowest amount (0.3 g/transfection) at which a dexamethasone-dependent effect was observed (Fig. 2B) . Furthermore, we have observed qualitatively similar dexamethasone-dependent negative regulation of these same vasopressin gene promoter constructs following their introduction into AtT-20 cells, which express endogenous GR (Iwasaki, Y., unpublished observations). Recently, activation of transcription by GR has been shown to require CBP (49) , and it has been suggested that intracellular levels of CBP may be limiting (50) . Thus, an explanation for our findings may be that glucocorticoid-activated GR within the nucleus binds to CBP, thereby decreasing CREB-CBP interaction, resulting in a decrease in PKA-stimulated transcription. By this mechanism, GR would not inhibit basal transcription, because nonphosphorylated CREB stimulates constitutive transcription via direct interaction with TFIID, without the involvement of CBP (44) . That GR-mediated inhibition of vasopressin promoter transcription was abolished in a GR mutant lacking the zinc finger domain raises the possibility that this motif may mediate interaction between GR and CBP. The switch from negative to positive regulation associated with this GR mutant suggests that GR may possess both activities, either of which predominates when the other is blocked. This model is consistent with recent studies that suggest that GR can modulate transcriptional regulation without DNA binding, and that the zinc finger domain of GR may play a role not only in DNA binding but also in homodimerization and interaction with other proteins (51) (52) (53) . This model is also consistent with our finding that glucocorticoid reduced PKA-activated transcription to a similar degree in vasopressin promoter constructs AVP3000 to AVP102, irrespective of the absolute level of activation by PKA (Fig. 5) . However, we cannot explain why dexamethasone did not suppress forskolin activation of construct AVP36, although in this case DNA within 7 nucleotides of the TATA box is deleted, which might normally bind components of the basal transcription complex involved in glucocorticoid-mediated negative regulation.
Our studies suggest that the positive and negative regulation of vasopressin gene transcription is complex. They should guide future experiments that will more directly examine the physical interaction of transcription factors with the vasopressin gene promoter, to more precisely characterize the nature of this regulation.
